TrialJournal of hematology & oncology2014

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.

Bertrand Coiffier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.